Article

bizjournals.com on 2020-01-30 16:20

Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drug

Biogen

Related news

Biogen trial drug shows promise in fight against Alzheimer's The Japan Times
Arizona , Phoenix , Switzerland , United States
Biogen pays California biotech $350M upfront for Alzheimer's gene therapy bizjournals.com
California
WAlzheimer's drug from Biogen, partner receives FDA approval wraltechwire.com
Cambridge , Japan
Biogen analysts pounce on 'thin' Alzheimer's trial data bizjournals.com
Biogen says new drug shows promise in combating Alzheimer's metro.us
Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conference bizjournals.com
Biogen shares soar as FDA reviewers support Alzheimer's drug Sydney Morning Herald
Wall Street , Massachusetts , Cambridge
Biogen buoyed despite Alzheimer's drug's new, more restrictive label bizjournals.com
Biogen to cease production of controversial Alzheimer's drug POLITICO
Biogen doubles down on Alzheimer's with new collaboration deal bizjournals.com
Biogen lays out plans for confirmatory study of Alzheimer's drug bizjournals.com
Biogen reworks Alzheimer's drug pacts in bullish move bizjournals.com
Biogen stock gains on leaked Alzheimer's drug data bizjournals.com
San Diego
In reversal, Biogen to file for approval of Alzheimer's drug bizjournals.com
Biogen And Eisai Present Positive Results For Experimental Alzheimer's Drug Forbes
Experts question Alzheimer's treatment strategy after Biogen failure bizjournals.com